2023
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
Shatsky R, Thomas A, Yau C, Chien A, Falkson C, Stringer-Reasor E, Omene C, Trivedi M, Boughey J, Sanford A, Arora M, Sanft T, Nanda R, Isaacs C, Brown T, Hylton N, DeMichele A, Yee D, Esserman L. Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL. Journal Of Clinical Oncology 2023, 41: lba612-lba612. DOI: 10.1200/jco.2023.41.17_suppl.lba612.Peer-Reviewed Original ResearchImmune related adverse eventsWeeks x 4High-risk breast cancerPD-1 inhibitorsPathologic complete responseOral paclitaxelPeripheral neuropathyControl armBreast cancerRates of neutropeniaEfficacy of immunotherapyPhase 2 trialRelated adverse eventsHigh-risk cancerBiomarker subtypesI-SPY2Neoadjuvant agentWeekly trastuzumabOral agentsPrimary endpointAdverse eventsComplete responseOral combinationCombination therapyPump inhibitors
2021
Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith H, Schwab R, Yau C, Stringer-Reasor E, Wei S, Chien A, Albain K, Kalinsky K, Wallace A, Elias A, Yee D, Clark A, Boughey J, Han H, Nanda R, Isaacs C, Mitri Z, Lang J, Thomas A, Sanft T, DeMichele A, Perlmutter J, Rugo H, Hylton N, Symmans W, Melisko M, van't Veer L, Wilson A, Asare S, Sanil A, Berry D, Esserman L. Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2021, 81: pd1-10-pd1-10. DOI: 10.1158/1538-7445.sabcs20-pd1-10.Peer-Reviewed Original ResearchStage II/III breast cancerWeekly x 4I-SPY 2 TRIALI-SPY 2PCR rateBreast cancerI-SPYPeripheral neuropathyHigh-risk stage II/III breast cancerTumor samplesRates of peripheral neuropathyControl armEvaluate novel agentsPathological complete responsePhase 2 trialTreatment of angiosarcomaModerate to high expressionSide effect profileTime of surgeryBayesian predictive probability of successBreast tumor samplesAntibody drug conjugatesHR-HER2Complete responseNeoadjuvant therapy